Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment

OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychiatric services (Washington, D.C.) D.C.), 2001-04, Vol.52 (4), p.501-507
Hauptverfasser: Noordsy, Douglas L., O'Keefe, Christopher, Mueser, Kim T., Xie, Haiyi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 507
container_issue 4
container_start_page 501
container_title Psychiatric services (Washington, D.C.)
container_volume 52
creator Noordsy, Douglas L.
O'Keefe, Christopher
Mueser, Kim T.
Xie, Haiyi
description OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.
doi_str_mv 10.1176/appi.ps.52.4.501
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77012569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77012569</sourcerecordid><originalsourceid>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</originalsourceid><addsrcrecordid>eNp1kEtLAzEURoMotlb3rmRAcDfjTSYPZyn1CZUKrbgMmTRDp3QmY5LBx683tUVXru5dnO9-l4PQKYYMY8EvVdfVWeczRjKaMcB7aIgZE2khAPbjDoKlROQwQEferwAAC8wP0QBjIigtxBDdzOqP9Mm2YZlM-6BtY3xSWZc8q1CbNvjkdWmT2Xsd9NIskmCT6Vq1X6qrW5PMnVGhidQxOqjU2puT3Ryhl7vb-fghnUzvH8fXk1RRxkMqNIAmmqnCCMEVxcAXvAANJRClckKAkWrBK0bLEoTAhDBtODUxcMULQvIRutje7Zx9640Psqm9Nuv4krG9l0IAJowXEYQtqJ313plKdq5ulPuUGOTGnNyYk52XjEgqo7kYOdvd7svGLP4CO1URON8Bymu1rpxqde1_uYIymm-a0y31U7CyvWujkf9rvwEPyIWN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77012569</pqid></control><display><type>article</type><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</creator><creatorcontrib>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</creatorcontrib><description>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</description><identifier>ISSN: 1075-2730</identifier><identifier>EISSN: 1557-9700</identifier><identifier>DOI: 10.1176/appi.ps.52.4.501</identifier><identifier>PMID: 11274497</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Antipsychotic Agents - administration &amp; dosage ; Antipsychotic Agents - therapeutic use ; Benzodiazepines ; Biological and medical sciences ; Brief Psychiatric Rating Scale ; Chlorpromazine - administration &amp; dosage ; Chlorpromazine - therapeutic use ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Medical sciences ; Mental Disorders - diagnosis ; Mental Disorders - drug therapy ; Mental Disorders - psychology ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Pirenzepine - administration &amp; dosage ; Pirenzepine - analogs &amp; derivatives ; Pirenzepine - therapeutic use ; Prospective Studies ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Severity of Illness Index ; Time Factors ; Treatment Outcome</subject><ispartof>Psychiatric services (Washington, D.C.), 2001-04, Vol.52 (4), p.501-507</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</citedby><cites>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ps.52.4.501$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ps.52.4.501$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2853,2857,21624,21625,21626,21627,27922,27923,77561,77562,77564,77569</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=945439$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11274497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noordsy, Douglas L.</creatorcontrib><creatorcontrib>O'Keefe, Christopher</creatorcontrib><creatorcontrib>Mueser, Kim T.</creatorcontrib><creatorcontrib>Xie, Haiyi</creatorcontrib><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><title>Psychiatric services (Washington, D.C.)</title><addtitle>Psychiatr Serv</addtitle><description>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</description><subject>Adult</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines</subject><subject>Biological and medical sciences</subject><subject>Brief Psychiatric Rating Scale</subject><subject>Chlorpromazine - administration &amp; dosage</subject><subject>Chlorpromazine - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Disorders - diagnosis</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - psychology</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pirenzepine - administration &amp; dosage</subject><subject>Pirenzepine - analogs &amp; derivatives</subject><subject>Pirenzepine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1075-2730</issn><issn>1557-9700</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEURoMotlb3rmRAcDfjTSYPZyn1CZUKrbgMmTRDp3QmY5LBx683tUVXru5dnO9-l4PQKYYMY8EvVdfVWeczRjKaMcB7aIgZE2khAPbjDoKlROQwQEferwAAC8wP0QBjIigtxBDdzOqP9Mm2YZlM-6BtY3xSWZc8q1CbNvjkdWmT2Xsd9NIskmCT6Vq1X6qrW5PMnVGhidQxOqjU2puT3Ryhl7vb-fghnUzvH8fXk1RRxkMqNIAmmqnCCMEVxcAXvAANJRClckKAkWrBK0bLEoTAhDBtODUxcMULQvIRutje7Zx9640Psqm9Nuv4krG9l0IAJowXEYQtqJ313plKdq5ulPuUGOTGnNyYk52XjEgqo7kYOdvd7svGLP4CO1URON8Bymu1rpxqde1_uYIymm-a0y31U7CyvWujkf9rvwEPyIWN</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>Noordsy, Douglas L.</creator><creator>O'Keefe, Christopher</creator><creator>Mueser, Kim T.</creator><creator>Xie, Haiyi</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><author>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines</topic><topic>Biological and medical sciences</topic><topic>Brief Psychiatric Rating Scale</topic><topic>Chlorpromazine - administration &amp; dosage</topic><topic>Chlorpromazine - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Disorders - diagnosis</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - psychology</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pirenzepine - administration &amp; dosage</topic><topic>Pirenzepine - analogs &amp; derivatives</topic><topic>Pirenzepine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noordsy, Douglas L.</creatorcontrib><creatorcontrib>O'Keefe, Christopher</creatorcontrib><creatorcontrib>Mueser, Kim T.</creatorcontrib><creatorcontrib>Xie, Haiyi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric services (Washington, D.C.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noordsy, Douglas L.</au><au>O'Keefe, Christopher</au><au>Mueser, Kim T.</au><au>Xie, Haiyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</atitle><jtitle>Psychiatric services (Washington, D.C.)</jtitle><addtitle>Psychiatr Serv</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>52</volume><issue>4</issue><spage>501</spage><epage>507</epage><pages>501-507</pages><issn>1075-2730</issn><eissn>1557-9700</eissn><abstract>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>11274497</pmid><doi>10.1176/appi.ps.52.4.501</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1075-2730
ispartof Psychiatric services (Washington, D.C.), 2001-04, Vol.52 (4), p.501-507
issn 1075-2730
1557-9700
language eng
recordid cdi_proquest_miscellaneous_77012569
source MEDLINE; American Psychiatric Publishing Journals (1997-Present); Psychiatry Legacy Collection Online Journals 1844-1996; EZB-FREE-00999 freely available EZB journals
subjects Adult
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - therapeutic use
Benzodiazepines
Biological and medical sciences
Brief Psychiatric Rating Scale
Chlorpromazine - administration & dosage
Chlorpromazine - therapeutic use
Dose-Response Relationship, Drug
Female
Humans
Male
Medical sciences
Mental Disorders - diagnosis
Mental Disorders - drug therapy
Mental Disorders - psychology
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Pirenzepine - administration & dosage
Pirenzepine - analogs & derivatives
Pirenzepine - therapeutic use
Prospective Studies
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Severity of Illness Index
Time Factors
Treatment Outcome
title Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six-Month%20Outcomes%20for%20Patients%20Who%20Switched%20to%20Olanzapine%20Treatment&rft.jtitle=Psychiatric%20services%20(Washington,%20D.C.)&rft.au=Noordsy,%20Douglas%20L.&rft.date=2001-04-01&rft.volume=52&rft.issue=4&rft.spage=501&rft.epage=507&rft.pages=501-507&rft.issn=1075-2730&rft.eissn=1557-9700&rft_id=info:doi/10.1176/appi.ps.52.4.501&rft_dat=%3Cproquest_cross%3E77012569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77012569&rft_id=info:pmid/11274497&rfr_iscdi=true